The present status and future prospects of peptide-based cancer vaccines

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond

(2016) K. F. Bol et al.   CLINICAL CANCER RESEARCH

An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs

(2016) Masatoshi Hirayama et al.   OncoImmunology

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

(2015) Deepa K. Krishnadas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses

(2015) Yasuharu Nishimura et al.   CANCER SCIENCE

TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity

(2015) Jennifer D Stone et al.   CURRENT OPINION IN IMMUNOLOGY

Therapeutic cancer vaccines

(2015) Cornelis J.M. Melief et al.   JOURNAL OF CLINICAL INVESTIGATION

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

(2015) Yanping Xiao et al.   Cancer Discovery

Identification of glypican-3-derived long peptides activating both CD8+and CD4+T cells; prolonged overall survival in cancer patients with Th cell response

(2015) Mohammad A. Sayem et al.   OncoImmunology

Trial Watch: Peptide-based anticancer vaccines

(2015) Jonathan Pol et al.   OncoImmunology

Classification of current anticancer immunotherapies

(2015) Lorenzo Galluzzi et al.   Oncotarget

Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS

(2014) Y. Yoshitake et al.   CLINICAL CANCER RESEARCH

Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

(2014) Hisae Iinuma et al.   Journal of Translational Medicine

Clinical use of dendritic cells for cancer therapy

(2014) Sébastien Anguille et al.   LANCET ONCOLOGY

A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide

(2014) Athanasios Kotsakis et al.   LUNG CANCER

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

(2014) Carsten Linnemann et al.   NATURE MEDICINE

Therapeutic vaccines for cancer: an overview of clinical trials

(2014) Ignacio Melero et al.   Nature Reviews Clinical Oncology

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand-Peptide Conjugates

(2014) G. G. Zom et al.   Cancer Immunology Research

Identification of immunogenic LY6K long peptide encompassing both CD4+and CD8+T-cell epitopes and eliciting CD4+T-cell immunity in patients with malignant disease

(2014) Yusuke Tomita et al.   OncoImmunology

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor

(2013) Y. Tomita et al.   CLINICAL CANCER RESEARCH

Identification of CDCA1-derived long peptides bearing both CD4+and CD8+T-cell epitopes: CDCA1-specific CD4+T-cell immunity in cancer patients

(2013) Yusuke Tomita et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

(2013) Hiroyuki Suzuki et al.   Journal of Translational Medicine

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

(2013) Mariette I E van Poelgeest et al.   Journal of Translational Medicine

T-helper-1-cell cytokines drive cancer into senescence

(2013) Heidi Braumüller et al.   NATURE

Adoptive cell therapy: Honing that killer instinct

(2013) Courtney Humphries   NATURE

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients

(2013) Ryuji Okuyama et al.   OncoImmunology

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Immunotherapy of cancer in 2012

(2012) John M. Kirkwood et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exploiting the Mutanome for Tumor Vaccination

(2012) J. C. Castle et al.   CANCER RESEARCH

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

(2012) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

(2012) Koji Kono et al.   Journal of Translational Medicine

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the tumor mutanome for personalized vaccination therapy

(2012) Sebastian Kreiter et al.   OncoImmunology

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

(2011) J. A. Kyte et al.   CLINICAL CANCER RESEARCH

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

(2011) P. F. Brunsvig et al.   CLINICAL CANCER RESEARCH

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes

(2010) R. Bos et al.   CANCER RESEARCH

Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells

(2010) Yusuke Tomita et al.   CANCER SCIENCE

Naive tumor-specific CD4+T cells differentiated in vivo eradicate established melanoma

(2010) Ying Xie et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

(2010) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells

(2009) V. Francois et al.   CANCER RESEARCH

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

(2009) Ninke Leffers et al.   INTERNATIONAL JOURNAL OF CANCER

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

(2009) Mary L. Disis et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

(2008) Martijn S. Bijker et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL

(2008) Michiko Harao et al.   INTERNATIONAL JOURNAL OF CANCER